Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Please share Science & Enterprise

Merger to Form Programmable Nano-Medicines Company

Molecule model in an open hand

A life science venture investor is merging two of its biotechnology portfolio companies to form a single developer of nanoscale medications with programmable properties. . . . → Read More: Merger to Form Programmable Nano-Medicines Company

Infographic – Q2 Tech Merger Values Up, Deals Down

Bar chart: Tech industry mergers and acquisitions by quarter, 2019 to Q2 2023

The value of mergers and acquisitions in the global technology sector rose for the first time in over a year in the second quarter of 2023, while M&A deal counts dropped somewhat. . . . → Read More: Infographic – Q2 Tech Merger Values Up, Deals Down

Regeneron Acquires Hearing Loss Biotech in $213M Deal

Headphones sound waves graphic

Regeneron Pharmaceuticals, a maker of synthetic biologic treatments, is acquiring Decibel Therapeutics, developer of gene therapies to treat hearing loss and balance disorders. . . . → Read More: Regeneron Acquires Hearing Loss Biotech in $213M Deal

Computational Drug Discovery Company Acquires A.I. Businesses

Synthetic biology

Two companies using artificial intelligence to advance biotechnology and design new therapies are merging with a computational-engineering drug discovery enterprise. . . . → Read More: Computational Drug Discovery Company Acquires A.I. Businesses

Cell Biology Tools Companies Merge in $57.8M Deal

DNA chip graphic

Two providers of technologies for cellular analysis are merging to form a new company focusing on cell biology research tools, in a sign of continued industry consolidation. . . . → Read More: Cell Biology Tools Companies Merge in $57.8M Deal

Mental Health VR Companies Merge, Raise $13M

Subway car interior

Two developers of virtual reality therapy technology for mental health disorders are combining their operations, and raising $13 million in venture funds. . . . → Read More: Mental Health VR Companies Merge, Raise $13M

Gut-Brain Meds Developer Going Public in Merger

Milk splashing

(Myriams-Fotos, Pixabay. https://pixabay.com/photos/milk-splash-drops-food-liquid-4755234/)

31 Oct. 2022. A developer of synthetic biology treatments for inflammatory and neurological disorders linked to the gut is becoming a public company through a special acquisition merger. Intrinsic Medicine Inc. in Seattle is joining with Phoenix Biotech Acquisition Corp. in Oakland, California, a special purpose acquisition company or SPAC, . . . → Read More: Gut-Brain Meds Developer Going Public in Merger

Immune Disease Biotech Acquired in $405M Deal

Human T-cell

A biotechnology developer of treatments for autoimmune disorders with checkpoint receptor proteins is acquired by drug maker Gilead Sciences. . . . → Read More: Immune Disease Biotech Acquired in $405M Deal

Ginkgo Acquires Biomaterials Maker as Industry Consolidates

Digital DNA

A developer of synthetic biology tools and components is acquiring a biological materials developer for its automation assets as the biotechnology industry consolidates. . . . → Read More: Ginkgo Acquires Biomaterials Maker as Industry Consolidates

Diabetes Cell Therapy Biotech Acquired in $320M Deal

Diabetes word cloud

A developer of therapies derived from stem cells to replace malfunctioning islet cells in people with type 1 diabetes was acquired by Vertex Pharmaceuticals. . . . → Read More: Diabetes Cell Therapy Biotech Acquired in $320M Deal